MYBL1 and pleomorphic xanthoastrocytoma: IDH-wildtype astrocytomas were the most heterogeneous molecular group as the grade II and grade III tumors were stratified into distinct methylation subclasses of glioblastoma or different molecular entities (i.e., low-grade glioma MYB/MYBL1 or (anaplastic) pleomorphic xanthoastrocytoma) that are not included in the category of “diffuse astrocytic and oligodendroglial tumors” in the WHO 2016 classification system.